DOR's Recent News Highlights:
On March 25, 2009, DOR announced that it entered into a $400,000 common stock equity investment agreement priced at market with its clinical trials management partner, Numoda Corporation.
On March 16, 2009, DOR announced the appointment of Gregg A. Lapointe, CPA, MBA to its Board of Directors.
On March 13, 2009, DOR announced the appointment of Brian L. Hamilton, MD, PhD as its Chief Medical Officer.
On February 12, 2009, DOR announced that it entered into a partnering agreement with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization in North America of orBec(R) (oral beclomethasone dipropionate or Oral BDP).
On January 27, 2009, DOR announced the appointment of Christopher J. Schaber, PhD to the BioNJ Board of Directors.
On January 26, 2009, DOR announced the formation of a Medical Advisory Board to provide medical/clinical strategic guidance as it relates to the development of DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP) for the prevention of acute radiation enteritis.
On January 20, 2009, DOR announced the engagement of Amper, Politziner & Mattia, LLP to serve as its independent registered public accounting and auditing firm.
On January 12, 2009, DOR announced that it had entered into stock purchase agreements with institutional and accredited investors totaling approximately $2.4 million.
On January 6, 2009, DOR announced that its DOR201 program received "Fast Track" designation from the FDA for the treatment of radiation enteritis. Previously in December, the FDA had completed its review of the Investigational New Drug (IND) application for DOR201, clearing the way for DOR to begin clinical trials.
On January 5, 2009, DOR announced that it re
|SOURCE DOR BioPharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved